NCT07212868 - The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

May 1, 2030

Study Completion Date

June 30, 2030

Conditions

Non-Diabetic

Interventions

DRUG

REMD-477 versus Placebo

Placebo versus glucagon receptor antagonist using a human monoclonal antibody with a high level of antagonistic effect against human glucagon receptor.

OTHER

Exogenous glucagon versus saline infusion

The effect of increased glucagon concentrations in plasma on glucose metabolism during glucose clamp will be studied.

Trial Locations (2)

78207

Texas Diabetes Institute - University Health System, San Antonio

78229

University of Texas San Antonio, San Antonio

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER